Cumulus Neuroscience published final results from its CNS-102 study in Scientific Reports.
The paper demonstrates that the at-home NeuLogiq platform was feasible, well tolerated, and rated highly usable by people living with amyotrophic lateral sclerosis and frontotemporal dementia over an eight-month protocol.
The platform combines a 16-channel wireless dry-sensor EEG headset with a tablet-delivered battery of gamified neurocognitive tasks covering executive function, memory, language, social cognition and psychomotor speed.
According to the company, 82% of ALS participants rated the platform easy to use, and 75% rated their overall opinion of the technology positive or very positive.
Cumulus claims CNS-102 is the first published study to combine at-home EEG with a multi-domain cognitive assessment in this population and that exploratory longitudinal signals on speech fluency and emotion recognition were detected in the ALS cohort but not by the in-clinic neuropsychological battery, suggesting value in more frequent home-based multimodal sampling.
The study was conducted in collaboration with the PRECISIONALS initiative hosted by Trinity College Dublin.
